Kodiak Sciences Inc.
KOD
Rangering i aksjer
#3085
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Aksjekurs
$93.69
Sist synkronisert: 2026-10-20
Markedsverdi
$5.89B
Endring (1 dag)
2.56%
Endring (1 år)
393.11%
Land
US
Handel Kodiak Sciences Inc. (KOD)
Kategori
Healthcare
Historikk for aksjesplitt for Kodiak Sciences Inc. (KOD)
Aksjen Kodiak Sciences Inc. (symbol: KOD) har gjennomgått totalt 1 aksjesplitt.
Den nyeste splittelsen skjedde Feb 23, 2022.
Én KOD-aksje kjøpt før Feb 23, 2022 tilsvarer i dag 5 KOD-aksjer.
Den nyeste splittelsen skjedde Feb 23, 2022.
Én KOD-aksje kjøpt før Feb 23, 2022 tilsvarer i dag 5 KOD-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| 2022-02-23 | 5:1 | x5 | x5 |
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
